Organic Nanomaterials: Liposomes, Albumin, Dendrimer, Polymeric Nanoparticles

Kang, Keon Wook; Song, Min Kyoung

doi:10.1007/978-3-319-67720-0_5

Cited by 8 publications

(9 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, some NCs are very stable and difficult to be broken down, while some NCs are biodegradable and easy to be metabolized (Kang & Song, 2018). 72 After administration, NCs which are less than 6 nm in size can be excreted by renal within hours to days. The non-degradable nanocarriers which are larger than 6 nm in size are taken up by the mononuclear phagocyte system (MPS).…”

Section: Superparamagnetic Iron Oxide Nanoparticles As a Diagnostic Amentioning

confidence: 99%

<p>Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities</p>

Ruman

Fakurazi

Masarudin

et al. 2020

IJN

117

View full text Add to dashboard Cite

The development of therapeutics and theranostic nanodrug delivery systems have posed a challenging task for the current researchers due to the requirement of having various nanocarriers and active agents for better therapy, imaging, and controlled release of drugs efficiently in one platform. The conventional liver cancer chemotherapy has many negative effects such as multiple drug resistance (MDR), high clearance rate, severe side effects, unwanted drug distribution to the specific site of liver cancer and low concentration of drug that finally reaches liver cancer cells. Therefore, it is necessary to develop novel strategies and novel nanocarriers that will carry the drug molecules specific to the affected cancerous hepatocytes in an adequate amount and duration within the therapeutic window. Therapeutics and theranostic systems have advantages over conventional chemotherapy due to the high efficacy of drug loading or drug encapsulation efficiency, high cellular uptake, high drug release, and minimum side effects. These nanocarriers possess high drug accumulation in the tumor area while minimizing toxic effects on healthy tissues. This review focuses on the current research on nanocarrier-based therapeutics and theranostic drug delivery systems excluding the negative consequences of nanotechnology in the field of drug delivery systems. However, clinical developments of theranostics nanocarriers for liver cancer are considered outside of the scope of this article. This review discusses only the recent developments of nanocarrier-based drug delivery systems for liver cancer therapy and diagnosis. The negative consequences of individual nanocarrier in the drug delivery system will also not be covered in this review.

show abstract

Section: Superparamagnetic Iron Oxide Nanoparticles As a Diagnostic Amentioning

confidence: 99%

<p>Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities</p>

Ruman

Fakurazi

Masarudin

et al. 2020

IJN

117

View full text Add to dashboard Cite

show abstract

“…The radionuclide of choice is lipophilic enough to cross the lipid membrane of the nanomaterial, lipophobic enough to prevent radiometal solubility, and stable in the vesicle core. Moreover, functional groups on the radionuclide develop a charge in the aqueous environment of the nanomaterial core, aiding in entrapment with nanomaterial chelators (Kang and Song 2018 ; Ge et al 2020 ; Pérez-Medina et al 2020 ; Rhim et al 2015 ).…”

Section: Methods Of Radiolabeling Nanomaterialsmentioning

confidence: 99%

“…Organic nanomaterials include liposomes, exosomes, protein-based, polymeric micelles, dendrimers, and polymers, while inorganic nanomaterials include graphene, carbon, iron oxide, silica, gold, and quantum dots. Extensive reviews of nanomaterials investigated on the basis of this classification could be found elsewhere (Kang and Song 2018 ; Ranjbar Bahadori et al 2021 ). Nanomaterials can also be classified based on their dimension into 0D, 1D, 2D, and 3D nanomaterials.…”

Section: Basic Concepts For Nano-radiopharmaceuticalsmentioning

confidence: 99%

Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts

2023

View full text Add to dashboard Cite

In the last three decades, radiopharmaceuticals have proven their effectiveness for cancer diagnosis and therapy. In parallel, the advances in nanotechnology have fueled a plethora of applications in biology and medicine. A convergence of these disciplines has emerged more recently with the advent of nanotechnology-aided radiopharmaceuticals. Capitalizing on the unique physical and functional properties of nanoparticles, radiolabeled nanomaterials or nano-radiopharmaceuticals have the potential to enhance imaging and therapy of human diseases. This article provides an overview of various radionuclides used in diagnostic, therapeutic, and theranostic applications, radionuclide production through different techniques, conventional radionuclide delivery systems, and advancements in the delivery systems for nanomaterials. The review also provides insights into fundamental concepts necessary to improve currently available radionuclide agents and formulate new nano-radiopharmaceuticals.

show abstract

“…128 Abraxane® is an albumin nanoparticle-bound PTX and the first anti-cancer drug based on albumin in the USA authorized by the FDA for breast cancer treatment in 2005. 127 Dina et al prepared TMZ-loaded ANPs for the first time to target GL261 and BL6 cells. They loaded TMZ into ANPs using the desolvation method.…”

Section: Biomaterials Sciencementioning

confidence: 99%